|Budget Amount *help
¥47,060,000 (Direct Cost: ¥36,200,000、Indirect Cost: ¥10,860,000)
Fiscal Year 2011: ¥7,020,000 (Direct Cost: ¥5,400,000、Indirect Cost: ¥1,620,000)
Fiscal Year 2010: ¥11,700,000 (Direct Cost: ¥9,000,000、Indirect Cost: ¥2,700,000)
Fiscal Year 2009: ¥14,430,000 (Direct Cost: ¥11,100,000、Indirect Cost: ¥3,330,000)
Fiscal Year 2008: ¥13,910,000 (Direct Cost: ¥10,700,000、Indirect Cost: ¥3,210,000)
We focused the biofilm-forming bacteria in the infected root canal and out of the apical foramen, and aimed at the development of the microbiological diagnostic method of refractory periapical periodontitis. The other purpose was the development of the anti-biofilm drugs possessed inhibition of biofilm growth and suppression of preexisting biofilm ability using the biofilm-related gene or the drug associated with the quorum sensing inhibitor and anti-microbial agent.
The specific bacterial species were frequently associated with the extraradicular biofilm formation, and they relate to some clinical symptoms. In addition, we have discovered the biofilm-associated gene, and the conventional antibiotics or the quorum sensing related material indicating the anti-biofilm action. And we built up the basis for the clinical application of the chemical and genetic biofilm control methods.
I take pride in these results of the research giving the suggestion that is useful for the establishment of a new treatment strategy of refractory periapical periodontitis.